Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall F Holcombe

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Molecular Nutrition & Food Research|May 28, 2008
Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer preventionChristopher Hope, Kestutis Planutis, Marina Planutiene, et al.
Gynecologic Oncology|May 5, 2012
Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancerThanh H Dellinger, Kestutis Planutis, Danielle D Jandial, et al.
Case Reports in Oncological Medicine|January 16, 2016
An Unusual Course of Metastatic Gastroesophageal CancerWilliam H Smith, Sofya Pintova, Christopher J DiMaio, et al.
International Journal of Oncology|September 6, 2005
Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpressionAnthony Nguyen, Andrea Rosner, Tatjana Milovanovic, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer CareRandall F Holcombe, Claire F Verschraegen, Andrew E Chapman, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2014
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsMatthew D Galsky, Marshall Posner, Randall F Holcombe, et al.
Molecular Cancer Therapeutics|January 29, 2009
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cellsYaxiong Tang, Anne R Simoneau, Wu-xiang Liao, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsBenjamin A Weinberg, Joanne Xiu, Michael R Lindberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2021
Status of Cancer Care at Network Sites of the Nation's Academic Cancer CentersStanton L Gerson, Kate Shaw, Louis B Harrison, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Molecular Nutrition & Food Research|May 28, 2008
Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer preventionChristopher Hope, Kestutis Planutis, Marina Planutiene, et al.
Gynecologic Oncology|May 5, 2012
Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancerThanh H Dellinger, Kestutis Planutis, Danielle D Jandial, et al.
Case Reports in Oncological Medicine|January 16, 2016
An Unusual Course of Metastatic Gastroesophageal CancerWilliam H Smith, Sofya Pintova, Christopher J DiMaio, et al.
International Journal of Oncology|September 6, 2005
Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpressionAnthony Nguyen, Andrea Rosner, Tatjana Milovanovic, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer CareRandall F Holcombe, Claire F Verschraegen, Andrew E Chapman, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2014
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsMatthew D Galsky, Marshall Posner, Randall F Holcombe, et al.
Molecular Cancer Therapeutics|January 29, 2009
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cellsYaxiong Tang, Anne R Simoneau, Wu-xiang Liao, et al.
Journal of Gastrointestinal Oncology|August 9, 2019
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsBenjamin A Weinberg, Joanne Xiu, Michael R Lindberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2021
Status of Cancer Care at Network Sites of the Nation's Academic Cancer CentersStanton L Gerson, Kate Shaw, Louis B Harrison, et al.
Pageof 8